Short Interest in Decoy Therapeutics (NASDAQ:DCOY) Drops By 84.7%

Decoy Therapeutics (NASDAQ:DCOY) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totaling 23,986 shares, a decrease of 84.7% from the June 30th total of 156,313 shares. Based on an average daily volume of 44,863 shares, the days-to-cover ratio is presently 0.5 days. Currently, 4.6% of the company’s stock are short sold.

Decoy Therapeutics Trading Up 2.0%

Shares of NASDAQ:DCOY traded up $0.10 on Friday, hitting $5.04. The company had a trading volume of 9,632 shares, compared to its average volume of 683,977. The company has a market cap of $2.68 million, a PE ratio of -0.05 and a beta of 0.59. The stock’s 50 day moving average is $6.44. Decoy Therapeutics has a 1-year low of $4.32 and a 1-year high of $415.80.

Decoy Therapeutics (NASDAQ:DCOY) last posted its earnings results on Friday, May 8th. The company reported ($4.18) earnings per share (EPS) for the quarter. On average, equities analysts predict that Decoy Therapeutics will post -12.97 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, June 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Decoy Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.